ALKS (Alkermes) Stock Based Compensation : $102 Mil (TTM As of Sep. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Alkermes Stock Based Compensation?

Alkermes's Stock Based Compensation for the three months ended in Sep. 2024 was $23 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was $102 Mil.

Alkermes Stock Based Compensation Historical Data

The historical data trend for Alkermes's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Stock Based Compensation Chart

Alkermes Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

100.98

90.16

87.62

94.25

100.91

Alkermes Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Stock Based Compensation	Get a 7-Day Free Trial															23.92	25.84	32.76	20.60	22.53

Alkermes Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $102 Mil.

Alkermes Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Alkermes's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Alkermes Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

8AK:Germany 8AK:Germany

Address

1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6

Website

https://www.alkermes.com

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Executives

Craig C. Hopkinson	officer: SVP, Med Dev/Med Affairs, CMO	852 WINTER STREET, WALTHAM MA 02451
Christian Todd Nichols	officer: SVP, Chief Commercial Officer	852 WINTER STREET, WALTHAM MA 02451
Cato T Laurencin	director	C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Nancy Wysenski	director	2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr.	director	ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright	director	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine	officer: SVP, Corp Dev., Alkermes, Inc.	88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops	director, officer: Director and CEO, Alkermes plc	10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke	officer: President, Alkermes plc	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson	officer: EVP, Chief Operating Officer	852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Emily Peterson Alva	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown	officer: VP, Finance & CAO	14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon	director	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin	officer: SVP, CLO, Alkermes, Inc.	852 WINTER STREET, WALTHAM MA 02451